Get the Stockscreener App
4.59
1.77%
0.08
After Hours:
4.57
-0.02
-0.44%
Verve Therapeutics Inc stock is traded at $4.59, with a volume of 2.59M.
It is up +1.77% in the last 24 hours and down -27.37% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$4.51
Open:
$4.56
24h Volume:
2.59M
Relative Volume:
1.05
Market Cap:
$365.84M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-1.7722
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
+50.49%
1M Performance:
-27.37%
6M Performance:
-15.93%
1Y Performance:
-31.90%
1-Day Range:
$4.43
$4.84
1-Week Range:
$3.045
$5.81
52-Week Range:
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
4.59 | 365.84M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus
Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - Nasdaq
Verve impresses investors with second shot at PCSK9 - biocentury.com
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade - MarketScreener
Why Verve Therapeutics Is Skyrocketing Today - The Globe and Mail
Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Shakes Market with New Genomic Breakthrough - timothysykes.com
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral - MarketScreener
Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results - insights.citeline.com
Early stage cardio data from Verve bump the stock - BioWorld MedTech
Assessing Verve Therapeutics: Insights From 4 Financial Analysts - Benzinga
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Yahoo Finance
This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. - Barron's
Verve shares soar after new gene-editing trial shows no safety concerns - The Boston Globe
Verve Therapeutics: FDA Nod Sparks Stock Surge - timothysykes.com
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment? - RagingBull
Verve’s second swing at gene editing for heart disease shows early promise - BioPharma Dive
Verve Shares Soar After New Gene-Editing Trial Shows No Safety Concerns - Bloomberg.com
Verve Therapeutics Stock Rise: Is It A Turning Point? - timothysykes.com
Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial - MarketScreener
Verve Therapeutics reports promising trial results for cholesterol drug By Investing.com - Investing.com Canada
Verve Therapeutics reports promising trial results for cholesterol drug - Investing.com Australia
Verve Therapeutics stock soars on positive clinical trial results By Investing.com - Investing.com Nigeria
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Breakthrough: New Gene Editing Drug Cuts Bad Cholesterol by 53% in Heart Disease Patients - Stock Titan
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - ACCESS Newswire
Verve stock gains on FDA fast track tag (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Revolutionary Gene Editing Drug for Heart Disease Earns FDA Fast Track Status - Stock Titan
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV - ACCESS Newswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Strengthens Team with Strategic Equity Awards Worth $232K - Stock Titan
Verve Therapeutics CEO Sekar sells $40,761 in stock By Investing.com - Investing.com South Africa
Verve therapeutics CAO Joan Nickerson sells $11,524 in stock - Investing.com India
Verve Therapeutics CEO Sekar sells $40,761 in stock - Investing.com India
Verve Therapeutics Executives Sell Shares - TradingView
Verve therapeutics CAO Joan Nickerson sells $11,524 in stock By Investing.com - Investing.com UK
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Insider Monkey
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):